Pay in 4 interest-free payments of $6.87 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
But, like all studies, many others show no significant difference
We summarize mechanistic insights across cellular and molecular domains, critically appraise preclinical and clinical findings, and discuss translational challenges that include bioavailability and brain penetration, study heterogeneity, biomarker guided stratification, and pediatric safety
The product is intended strictly for laboratory and research use only
Methods: Sixty four cirrhotic patients with advanced HCC (56 males, mean age 67 years, 22 with diabetes, CPT-A=45/B=19, mean MELD-Na=11, ALBI grade I=20/grade II=38, 28 with varices, 18 with extrahepatic disease, 24 with macrovascular invasion) who either initially presented in the BCLC-C stage and were treated with ATZ/BEV (group A, N=23) or TKIs (group B, N=15) or who migrated from BCLC-A to BCLC-C within 2 years after LR or RFA and were treated with ATZ/BEV (group C, N=12) or TKIs (group D, N=14) were evaluated
US$ 28.13
US$ 20.52
US$ 22.87
US$ 29.07
